Single Agent Asciminib

Phase 2Small molecule

Single Agent Asciminib is one of 3 small molecule programs targeting Chronic Myeloid Leukemia, Chronic Phase. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Myeloid Leukemia, Chronic PhaseActive, not recruiting

Chronic Myeloid Leukemia, Chronic PhasePhase 2

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Chronic Myeloid Leukemia, Chronic Phase

#DrugCompanyPhaseTrials

Radotinib Hcl

IIl-Yang Pharm. Co., Ltd.

Phase 3

1 2

Radotinib

IIl-Yang Pharm. Co., Ltd.

Phase 3

1 3

Single Agent Asciminib

AAugusta University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2032

Phase 2Active, not recruiting

Chronic Myeloid Leukemia, Chronic Phase

NCT05143840

Clinical

Trials by Indication[1]

Chronic Myeloid Leukemia, Chronic Phase1 trial

Asciminib as Initial Therapy With Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia Who do Not Achieve Optimal Response or a Deep Molecular Remission (ALERT CML)

Active, not recruiting·UUniversity of Alabama at Birmingham·Phase 2·NCT05143840·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Single Agent Asciminib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Single Agent Asciminib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Single Agent Asciminib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Augusta University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAugusta University

Single Agent Asciminib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2032

Trials by Indication[1]

Chronic Myeloid Leukemia, Chronic Phase1 trial

References

Drug Info

Quick Facts

Related News